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Early on, corticotropin-releasing factor (CRF), a hallmark brain peptide mediating many
components of the stress response, was shown to affect food intake inducing a robust
anorexigenic response when injected into the rodent brain. Subsequently, other members
of the CRF signaling family have been identified, namely urocortin (Ucn) 1, Ucn 2, and Ucn
3 which were also shown to decrease food intake upon central or peripheral injection.
However, the kinetics of feeding suppression was different with an early decrease
following intracerebroventricular injection of CRF and a delayed action of Ucns contrasting
with the early onset after systemic injection. CRF and Ucns bind to two distinct G-protein
coupled membrane receptors, the CRF1 and CRF2. New pharmacological tools such as
highly selective peptide CRF1 or CRF2 agonists or antagonists along with genetic knock-in
or knock-out models have allowed delineating the primary role of CRF2 involved in the
anorexic response to exogenous administration of CRF and Ucns. Several stressors trigger
behavioral changes including suppression of feeding behavior which are mediated by brain
CRF receptor activation. The present review will highlight the state-of-knowledge on the
effects and mechanisms of action of CRF/Ucns-CRF1/2 signaling under basal conditions
and the role in the alterations of food intake in response to stress.
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INTRODUCTION
Hans Selye was the first to introduce the biological concept and
term of stress based on similar macroscopic changes namely
the development of gastric erosions, involution of the lymphatic
organs and hypertrophy of the adrenal glands in response to
the exposure to a variety of noxious chemical agents or phys-
ical constraint in rats (Selye, 1936, 1976). Fourteen years later,
Geoffrey Harris showed that various stressors induced the release
of adrenocorticotropic hormone (ACTH) and provided the evi-
dence for the release of a hypothalamic factor acting via hypophy-
seal portal vessels (De Groot and Harris, 1950; Harris, 1950).
This concept was further supported by the purification of a
hypothalamic factor stimulating ACTH release from the rat pitu-
itary gland in 1955 (Guillemin and Rosenberg, 1955; Saffran
et al., 1955). Therefore, this factor—which eluded its identifica-
tion up to 1981—was named corticotropin-releasing factor (CRF)
(Guillemin and Rosenberg, 1955; Saffran et al., 1955). From
the beginning and with great foresight, Selye assumed that CRF
would be “the first mediator that integrates the adaptive bod-
ily response to stress” (Selye, 1976). After its identification and
characterization by Vale’s group as a 41 amino acid (aa) pep-
tide (Vale et al., 1981), numerous studies unraveled pleiotropic
stress-like actions induced by central injection of CRF beyond
the mere activation of the hypothalamus-pituitary-adrenal gland
axis. This includes the modulation of autonomic (sympathetic
and sacral parasympathetic activation), visceral and immune
functions but also behaviors (anxiogenic, reproductive and feed-
ing) (Dunn and Berridge, 1990; De Souza, 1995; Heinrichs et al.,
1997; Habib et al., 2000; Bale and Vale, 2004; Stengel and Taché,
2010).
It is well known that acute exposure to various stressors
such as visceral (physical) (Stengel et al., 2011), immune (Basa
et al., 2003; Wang et al., 2006; Stengel et al., 2010) and cognitive
(psychological) (Rybkin et al., 1997; Kinzig et al., 2008; Calvez
et al., 2011) stressors results in the suppression of food intake in
rodents. This inhibitory effect is largely mediated by the recruit-
ment of CRF signaling pathways in the brain. This is supported
by the activation of CRF-containing neurons and pituitary ACTH
release (Calvez et al., 2011; Wang et al., 2011a), the mimicry by
brain injection of CRF or related peptides, urocortins, and its
prevention by central injection of CRF receptor antagonists in
rats (Koob and Heinrichs, 1999). Interestingly, models of chronic
stress can have a dual effect on feeding and food preference in
experimental animals and humans (Dallman, 2010). Social defeat
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stress led to an increase in daily food intake in mice giving rise
to the recruitment of other/additional signaling systems under
these conditions, while chronic exposure to a battery of physi-
cal/environmental stressors reduces food intake and body weight
in rats (Lutter et al., 2008; Kumar et al., 2013).
The present review will describe first the state-of-knowledge
on the distribution of the CRF signaling systems including
CRF receptors, CRF, and urocortins in the brain and in the
periphery and the effects and mechanisms of central and periph-
eral injection of CRF and Ucns on food intake. Lastly, the role of
CRF receptor signaling pathways in themodulation of food intake
under conditions of stress will be highlighted.
THE CRF SIGNALING SYSTEM
LIGANDS: CRF AND UROCORTINS
CRF was identified in 1981 as a 41-aa hypothalamic peptide stim-
ulating the release of ACTH and β-endorphin from the anterior
part of the pituitary gland (Vale et al., 1981). Subsequently, other
members of the CRF family were identified (Vaughan et al., 1995;
Hsu and Hsueh, 2001; Lewis et al., 2001; Reyes et al., 2001),
namely Ucn 1, a 40-aa peptide sharing 45% sequence identity
with rat/human (r/h) CRF, Ucn 2, a 39-aa peptide sharing 34%
homology with r/h CRF and 42% with r/h Ucn 1 (Reyes et al.,
2001; Vaughan et al., 2013), and Ucn 3, a 38-aa peptide shar-
ing only 26% homology with r/h CRF and 21% with r/h Ucn
1, respectively (Lewis et al., 2001). These four peptides are all
derived from distinct genes highly conserved across mammalian,
non-mammalian, and invertebrate species consistent with the
physiological importance of this signaling system (Lovejoy and
de Lannoy, 2013).
CRF is widely distributed in the rodent brain with robust
expression at the mRNA and peptide level in the cerebral cortex,
amygdala, hippocampus, paraventricular nucleus of the hypotha-
lamus (PVN) and the Barrington’s nucleus (Valentino et al., 1994;
Wang et al., 2011a; Beckerman et al., 2013). Despite the fact
that urocortins show an extensive brain distribution, little neu-
roanatomical overlap exists between CRF and urocortins. Ucn
1 has limited brain distribution with one major expression site
which is the Edinger-Westphal nucleus (EWN) (Bittencourt et al.,
1999; Morin et al., 1999; Shah et al., 2013), and to a lesser
extent, the olfactory bulb, supraoptic nucleus (SON), ventro-
medial hypothalamus (VMH), lateral hypothalamic area, lateral
superior olive, ambiguus nucleus, dorsolateral tegmental nucleus,
linear and dorsal raphe nuclei, substantia nigra and cranial nerve
motor nuclei, namely facial and hypoglossal (Kozicz et al., 1998;
Bittencourt et al., 1999). Ucn 2 mRNA is found in the parvo-
and magnocellular part of the PVN, the arcuate nucleus of the
hypothalamus, SON, locus coeruleus, in cranial nerve motor
nuclei (trigeminal, facial and hypoglossal nuclei) and also in the
ventral horn of the spinal cord (Reyes et al., 2001; Mano-Otagiri
and Shibasaki, 2004). It is important to note that the knowledge
on Ucn 2′s distribution at the peptide level has been limited by the
lack of a specific Ucn 2 antibody. Lastly, Ucn 3mRNA and peptide
expression was detected in the amygdala, lateral septum, PVN,
VMH, basomedial nucleus of the stria terminalis, dorsal raphe
nucleus and in the area postrema (Lewis et al., 2001; Li et al., 2002;
Mano-Otagiri and Shibasaki, 2004; Venihaki et al., 2004).
Besides the widespread expression of CRF and related pep-
tides initially found in the central nervous system and thought
to be restricted to this site, as commonly observed for other pep-
tides, CRF and urocortins were also detected in visceral organs,
namely the lung, heart, spleen, adipose tissue, gonads (Boorse
and Denver, 2006; Wypior et al., 2011), pancreas (Li et al., 2003;
van der Meulen et al., 2012) and the gastrointestinal tract (Kozicz
and Arimura, 2002; Taché and Perdue, 2004; Taché and Bonaz,
2007; Yuan et al., 2012b) including the enteric nervous system
(Liu et al., 2006; Kimura et al., 2007). The past decade witnessed
an increasing knowledge on the peripheral expression and regu-
lation of CRF and urocortin signaling systems and recognition of
their implication in health and disease (Yuan et al., 2010; Buckinx
et al., 2011; Overman et al., 2012; Diaz and Smani, 2013; Onorati
et al., 2013).
CRF RECEPTORS
CRF ligands bind to CRF1 and/or CRF2 receptors consisting of
415 aa and 411 aa, respectively, that are encoded from two distinct
genes belonging to the B1 subfamily of seven-transmembrane
G-protein coupled receptors encompassing seven membrane-
spanning α-helices and an extracellular domain (Perrin and Vale,
1999). Both receptors share 70% identity within their species
homologue. The most variable component is the binding domain
that encompasses the N-terminal and the three extracellular coils
that share only 40% homology between the two receptor sub-
types. In their N-terminal extracellular region, CRF receptors
contain several potential points of N-glycosylation along with
several Cys residues that form disulfide bonds closely associated
with their functionality (Zmijewski and Slominski, 2010; Liapakis
et al., 2011). Various partial or total exon deletions or insertions
in the CRF gene - in some cases associated with a shift in the
open reading frame - generate multiple isoforms of CRF1 and
CRF2 receptors (Pisarchik and Slominski, 2001; Wu et al., 2007,
2011; Zmijewski and Slominski, 2010). Among the nine human
CRF1a−i variants, CRF1, also named CRF1a, is the main func-
tional receptor. The CRF1b isoform is also called pro-CRF1, and
this is the only variant coded by all 14 exons, leading to a 29-aa
insertion into the first intracellular loop which impairs agonist
binding and signaling activity compared to CRF1a (Markovic and
Grammatopoulos, 2010). The other isoforms CRF1c−i have the
exon 6 spliced out and in addition there are either cryptic exons
(1h), or the skipping of single (1c, 1d, and 1f) or multiple exons
(1e and 1g) (Pisarchik and Slominski, 2001, 2004;Wu et al., 2011).
The latest splice variant identified, CRF1i has a deletion of exon 4
and is functional. This was shown by the increased phosphory-
lation of the extracellular signal regulated kinase ½ (ERK1/2) in
response to Ucn 1 assessed in CRF1i transfected human embry-
onic kidney (HEK) cells (Wu et al., 2011). Other soluble isoforms
such as CRF1e and CRF1h may play a modulatory role as their
expression in transfected COS cells either decreased or ampli-
fied the CRF1α-coupled cAMP production induced by Ucn 1
(Pisarchik and Slominski, 2004).
With regards to the CRF2, three functional splice variants 2a,
2b, and 2c (also originally named 2α, 2β, and 2γ) derived from
alternative splicing exist in humans, while in other mammals only
two isoforms, CRF2a and CRF2b are expressed (Hauger et al.,
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2003; Hillhouse andGrammatopoulos, 2006). These isoforms dif-
fer structurally in their N-terminal extracellular domains (Hauger
et al., 2003). The 34-aa N-terminal extracellular region of the
CRF2a is replaced by 61 aa in the CRF2b and 20 aa in the CRF2c,
while the C-terminus is common to all CRF2 receptor splice vari-
ants (Miyata et al., 2001; Dautzenberg et al., 2004; Wu et al.,
2007). Sequence comparison indicated high homology between
rat and mouse CRF2a (94%) and mouse and human (92%)
(Dautzenberg et al., 2004). The presence of CRF2a in amphibian
species suggests an earliest occurrence of this splice variant dur-
ing vertebrate evolution, while the CRF2b is less conserved and
appears to be evolutionarily younger and is found only in mam-
mals (Dautzenberg et al., 2001). Recently, Chen et al. reported
a novel CRF2a splice variant in the mouse brain that includes
the first extracellular domain of the CRF2a receptor and acts as a
soluble binding protein (sCRF2a), thereby modulating the acces-
sibility and signaling (Chen et al., 2005). In the rat esophagus,
CRF2b wild-type transcript is predominantly expressed and in
addition, several new CRF2 splice variants including six CRF2a
isoforms were identified (Wu et al., 2007; Yuan et al., 2012b).
Similar to CRF, the CRF1 receptor displays a wide distri-
bution throughout the brain. In rats, the CRF1 is densely and
widely expressed in the forebrain, in the septal region and amyg-
dala (Justice et al., 2008), whereas basal expression is low in the
hypothalamus but up-regulated under conditions of stress and
also by CRF as a feed-forward mechanism (Bonaz and Rivest,
1998; Imaki et al., 2001; Konishi et al., 2003). Contrasting with
the wide distribution of the CRF1, expression of the CRF2 is
mainly found in the lateral septum, amygdala and hypothalamic
nuclei including the SON and VMH, dorsal raphe, area postrema
and nucleus tractus solitarius (Bittencourt and Sawchenko, 2000;
Chen et al., 2012). Both, CRF1 (laminae III-VIII) and CRF2
mRNA (laminae III-X) were also detected in the mouse spinal
cord (Korosi et al., 2007). In the periphery, the CRF1 was detected
in the anterior and intermediate lobe of the pituitary gland
(Turnbull and Rivier, 1997) and in the gastrointestinal tract more
prominently in colonic endocrine, neuronal and immune cells
(Chatzaki et al., 2004; Yuan et al., 2007, 2012a), while CRF2 was
found in the stomach including the luminal surface of the crypts
and in blood vessels of the submucosal layer (Chatzaki et al., 2004;
Yuan et al., 2012b).
Following the identification of CRF receptors, the characteri-
zation of binding affinities to endogenous ligands showed that the
CRF1 and CRF2 receptors display distinct affinities to CRF and
urocortins (Lewis et al., 2001; Hauger et al., 2003; Hillhouse and
Grammatopoulos, 2006). CRF displays a 10- to 40-fold higher
affinity for the CRF1 than the CRF2 receptor, whereas Ucn 1 binds
with equal affinity to both CRF receptors thereby displaying a
100-fold higher affinity to the CRF2 receptor compared to CRF
(Grace et al., 2007). It is important to note that so far no endoge-
nous selective ligand for the CRF1 has been identified. In contrast
to CRF and Ucn 1, Ucn 2, and Ucn 3 show high selectivity for the
CRF2 (Grace et al., 2007). In contrast to the CRF1 receptor iso-
forms, binding characteristics of the CRF receptor splice variants,
CRF2a, CRF2b, and CRF2c are almost identical with high affin-
ity for Ucn 1, Ucn 2, and Ucn 3, and lower affinity for r/hCRF
(Kostich et al., 1998; Ardati et al., 1999; Suman-Chauhan et al.,
1999; Lewis et al., 2001). However, the isoforms of CRF2a show
distinct pharmacological profiles; the mouse sCRF2a receptor has
very low affinity for Ucn 2 and Ucn 3, while binding to Ucn 1 (Ki
6.6 nM), and, to a lesser extent, to CRF (23 nM), and inhibits the
cAMP and ERK1/2-p42,44 responses to Ucn 1 and CRF (Chen
et al., 2005). In contrast, rat CRF2a−tr binds with low affinity to
CRF (Kd 12.7 nM) and does not bind to Ucn 1 (Miyata et al.,
1999).
FOOD INTAKE INHIBITORY ACTIONS OF BRAIN CRF AND
Ucns
It is well documented that members of the CRF family and more
prominently Ucns injected into the brain ventricle suppress food
intake in various species (Zorrilla et al., 2003; Wang et al., 2011b)
and increase energy expenditure (Richard et al., 2002). In ad libi-
tum fed rats, intracerebroventricular (icv) injection of CRF (Spina
et al., 1996), Ucn 1 (Spina et al., 1996; Yakabi et al., 2011), Ucn 2
(Ohata and Shibasaki, 2004), and Ucn 3 (Ohata and Shibasaki,
2004) decreases dark phase food intake. At the lowest icv doses,
Ucn 1 and Ucn 2 decrease food intake without inducing condi-
tioned taste aversion or visceral illness (Benoit et al., 2000; Inoue
et al., 2003; Zorrilla et al., 2004). It is to note that icv Ucn 1 is
more potent in suppressing food intake compared to CRF (Spina
et al., 1996), and Ucn 2 is 10-fold more potent than Ucn 3 in
reducing food intake (Pelleymounter et al., 2004). Kinetic stud-
ies also showed differences in the time course of food intake
suppression induced by icv injection of the CRF-related pep-
tides. CRF, a preferential CRF1 agonist, induces a rapid onset and
short-term reduction of the re-feeding response to an overnight
food deprivation in mice and rats (Ohata and Shibasaki, 2004;
Pelleymounter et al., 2004), while the dark phase food intake-
reducing effect of icv Ucn 2 or Ucn 3 is delayed (onset >3 h)
and long lasting in rats (Inoue et al., 2003; Zorrilla et al., 2004).
Conversely, in CRF1 deficient mice, icv Ucn 1 still induces a
delayed onset suppression of food intake while the early phase is
no longer observed (Bradbury et al., 2000). Similar to the acute
effects, under chronic conditions observed in mice overexpress-
ing CRF there is also a curtailing of the re-feeding response to a
fast (Stengel et al., 2009).
Convergent studies established the primary role of CRF2 in
mediating the anorexigenic effect of acute or repeated icv injec-
tions of CRF orUcns using complementary pharmacologic (selec-
tive CRF1 or CRF2 antagonists) (Smagin et al., 1998; Contarino
et al., 2000; Pelleymounter et al., 2000; Cullen et al., 2001; Sekino
et al., 2004) and gene deletion (CRF1 or CRF2 deficient mice)
(Bradbury et al., 2000) approaches in addition to the selective
CRF2 agonists, Ucn 2, and Ucn 3 (Cullen et al., 2001; Richard
et al., 2002; Zorrilla et al., 2003; Pelleymounter et al., 2004).
To date, the role of CRF1 in mediating the effects of icv CRF
and Ucn 1 appears to be less specific and is confounded by
competing behaviors (increased locomotion, grooming, anxiety-
or fear-like) induced by activation of the brain CRF1 signal-
ing pathway. This contrasts with icv Ucn 2 that does not elicit
behavioral arousal or anxiogenic effects (Pelleymounter et al.,
2000; Inoue et al., 2003; Zorrilla et al., 2004; Jochman et al.,
2005). Several brain sites expressing high concentrations of CRF2
(Bittencourt and Sawchenko, 2000) have been identified to be
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responsive to Ucns resulting in a CRF2-mediated anorexigenic
response, namely the lateral septum (Bakshi et al., 2007), PVN
(Currie et al., 2001), VMH (Ohata et al., 2000; Fekete et al.,
2007; Chen et al., 2012), medial amygdala (Fekete et al., 2007)
and dorsal raphe (Weitemier and Ryabinin, 2006). In addition,
hindbrain structures are involved based on the observation that
Ucn 1 injected into the fourth brain ventricle is still able to
reduce food intake in chronically decerebrated rats (Daniels et al.,
2004). Among those, the nucleus tractus solitarius has been
identified as a brainstem site responsive to Ucn 1 (Grill et al.,
2000).
Analysis of changes in feeding patterns associated with the
decreased food intake indicates that Ucn 2 injected icv reduced
the size of the meal (increased satiation) and the rate of inges-
tion, whereas meal frequency was not altered in rats (Inoue
et al., 2003). In addition, Ucn 3 injected icv, and even more
potently, when microinjected into the PVN and VMH, increased
inter-meal interval (induction of satiety), whereas meal size was
reduced (induction of satiation) at the highest dose only (Fekete
et al., 2007). In the medial amygdala, Ucn 3 was shown to pro-
mote nibbling (smaller but more frequent meal) (Fekete et al.,
2007), indicating the distinct modulation of feeding patterns by
Ucn 2 and Ucn 3 and the influence of brain sites of action.
The physiological relevance of the brain CRF2 signaling path-
ways in the regulation of feeding pattern and body weight is
supported by reports that CRF2 knockout mice showed increased
nocturnal food intake of normal chow (Tabarin et al., 2007) and
consumed more high fat food compared to their wild type lit-
termates (Bale et al., 2003). In addition, mice with a site specific
knockdown of CRF2 in the VMHusing small hairpin RNA exhibit
increased food intake under basal and stimulated conditions by
an overnight fast (Chao et al., 2012). This supports a role of
CRF2 in the VMH to curtail the cessation of eating. There is
also evidence that continuous icv infusion of the CRF2 antago-
nist antisauvagine-30 over 13 days increased food intake by 5%
in normal rats (Cullen et al., 2001), while chronic injection of a
CRF1 antagonist had no effect (Ohata et al., 2002). However mice
lacking Ucn 1 (Vetter et al., 2002) or Ucn 2 (Chen et al., 2006) have
a normal spontaneous food intake which may merely empha-
size the compensatory mechanisms by other endogenous peptide
members of the CRF family as genetic deficient Ucn 3 showed
elevated basal feeding and increased nocturnal food intake after
overnight fasting compared with the wild-type littermates (Chao
et al., 2012).
Several potential mechanisms could participate in icv Ucns-
induced anorexia. Central injection of CRF and Ucns potently
suppressed gastric emptying (Stengel and Taché, 2010) and
induces hyperglycemia (Brown et al., 1982; Chen et al., 2010).
Both effects are known to reduce feeding. Delayed gastric empty-
ing by slowing meal transit leads to accrual of food in the stomach
and consecutively to gastric satiety signaling to the brain (Phillips
and Powley, 1996) while elevated glucose exerts a direct action on
glucose sensing of hypothalamic neurons regulating food intake
(Levin, 2006; Cha et al., 2008). There is also evidence Ucn 1 icv
suppressed circulating acyl ghrelin (Yakabi et al., 2011), the only
known peripherally produced and centrally acting orexigenic hor-
mone (Hosoda et al., 2002; Stengel and Taché, 2012). Moreover,
Ucn 1 microinjected into the PVN increased plasma levels of
leptin (Kotz et al., 2002), a potent appetite suppressant (Keen-
Rhinehart et al., 2013). Future studies are needed to evaluate the
relative influence of these hormonal and functional alterations.
Besides the reduction in food intake, accumulated evidence
indicates that activation of brain CRF and Ucns signaling
pathways increases energy expenditure (Richard et al., 2002;
Kuperman and Chen, 2008). Sympathetically-regulated heat
production in brown adipose tissue (BAT) and lipid metabolism
contributes to the non-shivering thermogenic component of
energy expenditure and body weight regulation in rodents
(Landsberg et al., 1984). The icv injection of Ucns increases oxy-
gen consumption in rats as assessed by indirect calorimetry and
elevates body temperature resulting in increased energy expen-
diture (De Fanti and Martinez, 2002; Telegdy and Adamik, 2008).
Microinjection studies showed that CRF sites of action to increase
sympathetic nerve activity to interscapular BAT leading to BAT-
mediated thermogenesis and energy expenditure are located in
the medial preoptic area and dorsomedial hypothalamus unlike
the PVN or VMH (Egawa et al., 1990; Cerri and Morrison,
2006; Chao et al., 2012). However, during food restriction, Ucn
1 microinjected into the PVN increases thermogenic capacity by
elevating uncoupling protein-1 mRNA levels in BAT (Kotz et al.,
2002). The peptide at this site also changes energy substrate uti-
lization as shown by reduction of the respiratory quotient (QR)
under basal or NPY- or ghrelin-stimulated conditions (Currie
et al., 2001). The CRF2 seems to play a major role in the effects
on energy expenditure as mice lacking the CRF1 showed a greater
reduction in body weight following a 7-day icv infusion of Ucn
1 compared to their wild type littermates (Bradbury et al., 2000).
Additionally, the hyperthermic response to icv Ucn 2 and Ucn 3
was blocked by selective CRF2 receptor antagonists while CRF1
blockade had no effect (Telegdy et al., 2006). Moreover, selective
depletion of CRF2 in the VMH reduced lipolysis and increased
white fat (Chao et al., 2012).
FOOD INTAKE INHIBITORY ACTIONS OF PERIPHERAL CRF
AND Ucns
In addition to the central actions of CRF and Ucns, peripheral
(intraperitoneal, ip) injection of Ucns reduced food intake in sev-
eral species (Asakawa et al., 1999; Weisinger et al., 2000; Wang
et al., 2001; Tanaka et al., 2009) and repeated administration
also lowered body weight gain in mice (Asakawa et al., 1999).
The anorexigenic effect of Ucn 1 on re-feeding food intake was
stronger than that of cholecystokinin (CCK), leptin, and also CRF
in mice (Asakawa et al., 1999; Wang et al., 2001; Tanaka et al.,
2009). Interestingly, a synergistic interaction between ip injected
Ucn 1 and CCK-8 to reduce the feeding response to a fast and
liquid gastric emptying has been reported in mice (Gourcerol
et al., 2007). The demonstration that Ucn 1 injected peripherally
displays a similar potency as after icv injection supports a periph-
erally initiated mode of action (Cullen et al., 2001; Sinnayah et al.,
2003; Pelleymounter et al., 2004). However, it is to note that
systemic doses at which the preferential CRF1 agonist CRF, and
potent CRF1/CRF2 agonist, Ucn 1 decrease food intake are asso-
ciated with conditioned taste aversion and diarrhea (Fekete et al.,
2011), which are not observed at the lower anorexigenic doses of
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Ucn 1 given icv (Benoit et al., 2000; Inoue et al., 2003; Zorrilla
et al., 2004).
The reduction of food intake by ip Ucn 1 is CRF2 mediated as
the selective CRF2 antagonists, antisauvagine-30 and astressin2-
B blunted the reduction of food intake, whereas selective CRF1
antagonists did not (Weisinger et al., 2000; Wang et al., 2001,
2011b). In line with this finding, fasted mice lacking the CRF2
did not show a reduction of re-feeding food intake following ip
injected Ucn 1 (Wang et al., 2011b). The mechanisms through
which peripheral Ucn 1 exerts its anorexigenic effect do not
involve capsaicin sensory afferents, unlike ip CCK-8 tested under
the same conditions in mice (Wang et al., 2001). It was also
shown that the slowing of gastric emptying associated with ip
Ucn 1 accounts only for 35% of the reduction of food intake
induced by Ucn 1 (Wang et al., 2001). It may be speculated that
Ucn 1 acts through CRF2 densely expressed in appetite-/taste
aversion-regulating brain structures outside the blood brain bar-
rier, namely the area postrema (Sakai and Yamamoto, 1997;
Bittencourt and Sawchenko, 2000) shown to be activated by sys-
temic injection of Ucn 1 (Wang et al., 2000). This contention will
need to be further ascertained.
With regards to Ucn 2 and Ucn 3, both peptides induce a
rapid in onset and CRF2 mediated reduction of re-feeding food
intake after a fast and also dampen ad libitum dark phase food
intake with a potency of Ucn 2 > Ucn 3 in rodents (Wang
et al., 2001, 2011b; Gourcerol et al., 2007; Tanaka et al., 2009;
Fekete et al., 2011). In contrast to ip Ucn 1, Ucn 2 given ip at
an anorexigenic dose did not induce signs of taste aversion or
malaise (Fekete et al., 2011). Of interest, there is a synergistic
interaction between ip CCK-8 and Ucn 2 to reduce the re-feeding
response to a fast in mice which was also observed at the level
of vagal activity recorded from the gastric afferents in an in vitro
preparation (Gourcerol et al., 2007). This functional and electro-
physiological evidence combined with the expression of CRF2 in
rat nodose ganglia (Mercer et al., 1992; Lawrence et al., 2002)
point toward a role of vagal signaling in the mediation of ip Ucn
2 anorexic action that will need to be ascertained using vagal
deafferentation.
Additional insight into the characterization of the food intake-
reducing effects of peripheral administration of Ucns came from
studies detailing changes in meal patterns. Using the micropellet
technique, ip injection of Ucn 1 reduces the meal frequency (as a
characteristic of satiety), whereas the size of the meal (as a charac-
teristic of satiation) was less robustly altered during the re-feeding
period following a 24-h fast in rats (Fekete et al., 2011). Under
the same conditions, ip injection of Ucn 2 only reduced meal fre-
quency while not altering meal size (Fekete et al., 2011). These
data were recently extended to mice following ip injection of Ucn
2 using an automated episodic food intake monitoring system for
solid food: Ucn 2 reduced meal size and duration (induction of
satiation) but also increased meal frequency (reduction of satiety)
in overnight fasted mice (Wang et al., 2011b). Interestingly, when
injected ip in freely fed animals at the beginning of the dark phase,
Ucn 2 only affected satiation (reduction of meal size), whereas
satiety (indicated by the number of meals) was not altered (Wang
et al., 2011b) giving rise to a differential modulation of light and
dark phase feeding by Ucn 2.
INVOLVEMENT OF BRAIN CRF SIGNALING PATHWAYS IN
THE ANOREXIGENIC RESPONSE TO STRESS
Accumulated evidence supports a role of brain activation of
CRF signaling pathways in initiating the hypophagia and weight
loss induced by various types of stressors. This was established
using pharmacological approaches and to a lesser extent, genetic
deletion of CRF ligand or receptors in rodents. Earlier studies
showed that icv or 3rd ventricular injection of the non-selective
CRF1/CRF2, antagonist, α-helical CRF9−41 before exposure to
stressors prevented the decreased food intake observed after
acute exposure to restraint (Krahn et al., 1986; Shibasaki et al.,
1988; Smagin et al., 1999), 40min forced exercise (Rivest and
Richard, 1990) or emotional stress induced by a communica-
tion box paradigm (Hotta et al., 1999) while having no effect
on food intake under non-stressful conditions (Hotta et al.,
1999). The CRF antagonist injected into the 3rd ventricle also
blocked repeated restraint-induced weight loss (Smagin et al.,
1999). Subsequent studies to elucidate the importance of each
CRF receptor subtype in the stress-related decrease in food intake
indicated that either CRF receptor subtype alone or in combi-
nation can be involved in the hypophagia depending upon the
modality of the stressors. Evidence so far supports that the rela-
tive ability of selective CRF receptor subtype antagonists to block
stress-related anorexia is critically dependent upon specific brain
sites activated and related CRF ligands and receptor subtypes
recruited by different stressors. For instance, emotional stress trig-
gered by the communication box paradigm, foot shock and 1-h
restraint was reported to involve both CRF1 and CRF2 receptors
in rats as shown by partial or complete reversal induced by either
icv injection of CRF2 antagonist, antisauvagine-30 or periph-
eral administration of the CRF1 antagonist, CRA 1000 (Hotta
et al., 1999; Sekino et al., 2004). In mice, novelty/group sepa-
ration stress-induced reduction of food intake was curtailed by
icv pretreatment with the CRF1 antagonist, NBI- 127914 while
the potent CRF2 antagonist, astressin2-B had no effect (Saegusa
et al., 2011). Brain site specific targeting by CRF antagonists
indicates that the CRF1 antagonist, NBI-27914 microinjected
into the basolateral amygdala, unlike central amygdala, prevented
emotional stress (rat exposed to predator)-induced decreased
food intake and increased grooming while astressin2-B had no
effect (Jochman et al., 2005). By contrast, the CRF2 antagonist,
antisauvagine-30 microinjected into the lateral septum or poste-
rior division of the bed nucleus of the stria terminalis prevented
acute restraint-induced anorexia while the selective CRF1 antago-
nist, antalarmin had no effect in rats (Ohata and Shibasaki, 2011).
There is also evidence that CRF2 knockoutmice showed an abbre-
viated inhibition of food intake induced by restraint stress while
not being involved in the early orexigenic response (Tabarin et al.,
2007).
Of (patho)physiological relevance is the demonstration that
mutation in the CRF2 gene (Val411Met) was associated with an
early onset of severe obesity (Challis et al., 2004). Moreover,
several studies observed an association with a portion of
chromosome 7 also coding the CRF2 gene (7p15–7p21) and
body mass index (Wu et al., 2002), type 2 diabetes mel-
litus (Wiltshire et al., 2001) and also fat-free body mass
(Chagnon et al., 2000). Future studies are needed to corroborate
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these findings and investigate the consequences of these
associations.
SUMMARY
In summary, activation of CRF2 by Ucns reduced feeding after
central as well as peripheral injection without provoking behav-
ioral arousal or anxiogenic effects as observed for the anorexigenic
action induced by the activation CRF-CRF1 signaling path-
ways. Brain sites of action of Ucns involve the lateral septum,
PVN, VMH, medial amygdala, dorsal raphe and nucleus tractus
solitarius. Both, CRF1 and CRF2 receptor activation contributes
to the reduction of food intake associated with exposure to vari-
ous stressors. Their respective involvement is stressors and brain
sites specific mostly in relation with endogenous CRF ligands
and receptors recruited under the condition of stress. Still little is
known whether peripheral Ucn-CRF2 signaling plays a role in the
food intake response to visceral stressors. More research is needed
using site specific knockout or overexpression of CRF receptors
in order to address this issue and investigate the impact on food
intake and body weight.
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